<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00311467</url>
  </required_header>
  <id_info>
    <org_study_id>CECOG RCC 1.3.001</org_study_id>
    <nct_id>NCT00311467</nct_id>
  </id_info>
  <brief_title>Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma</brief_title>
  <official_title>Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma: a Prospective, Randomized, Multi-center phaseIII-Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central European Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central European Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, prospective randomised phase III study evaluating capecitabine in combination&#xD;
      with standard-immunotherapy versus standard-immunotherapy alone as first-line therapy in&#xD;
      patients with metastatic renal cell carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment plan Group A&#xD;
&#xD;
      Patients randomised to group A will receive treatment according to the following treatment&#xD;
      schedule:&#xD;
&#xD;
      Group A: Combined Chemo-Immunotherapy Chemotherapy: Mo-Fr Immunotherapy&#xD;
&#xD;
        -  Week 1:Capecitabine / Interferon;&#xD;
&#xD;
        -  Week 2:Capecitabine / Interferon;&#xD;
&#xD;
        -  Week 3:REST PERIOD / Interleukin;&#xD;
&#xD;
        -  Week 4:Capecitabine / Interleukin;&#xD;
&#xD;
        -  Week 5:Capecitabine / REST PERIOD;&#xD;
&#xD;
        -  Week 6:REST PERIOD / Interferon;&#xD;
&#xD;
        -  Week 7:Capecitabine / Interferon;&#xD;
&#xD;
        -  Week 8:Capecitabine / Interleukin;&#xD;
&#xD;
        -  Week 9:REST PERIOD / Interleukin;&#xD;
&#xD;
        -  Week 10:Capecitabine / REST PERIOD;&#xD;
&#xD;
        -  Week 11:Capecitabine / Interferon;&#xD;
&#xD;
        -  Week 12:REST PERIOD / Interferon;&#xD;
&#xD;
        -  Week 13:Capecitabine / Interleukin;&#xD;
&#xD;
        -  Week 14:Capecitabine / Interleukin;&#xD;
&#xD;
      DOSAGES AND ROUTES OF ADMINISTRATION:&#xD;
&#xD;
      Capecitabine orally from day 1 to 14 at a dose of 1000 mg/m2 twice daily every 21 days.&#xD;
&#xD;
      Interferon-alpha subcutaneously on days 1 + 3 + 5 weeks 1 + 2 +6 + 7,11+12 at a dose of 6&#xD;
      MIU/d.&#xD;
&#xD;
      Interleukin-2 subcutaneously on days 1 to 4 in weeks 3 + 4 +8 + 9,13+14 at a dose of 4.5&#xD;
      MIU/day.&#xD;
&#xD;
      Group B&#xD;
&#xD;
      Patients randomized to group B will receive treatment according to the same treatment&#xD;
      schedule and at the same dosages without capecitabine.&#xD;
&#xD;
      Efficacy evaluations will be performed every 14 weeks of treatment in both groups&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    no patient recruitment&#xD;
  </why_stopped>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary study objective is to investigate whether the addition of capecitabine to interferon-alpha-interleukin-2 based immunotherapy may improve progression free survival when compared to immunotherapy alone.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The study's secondary objectives are to investigate differences in response rates, safety and survival.</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Renal Cell Cancer</condition>
  <arm_group>
    <arm_group_label>Capecitabine and Interferon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combined Chemo-Immunotherapy Chemotherapy: Mo-Fr Immunotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interferon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to group B will receive treatment according to the same treatment schedule and at the same dosages without capecitabine.&#xD;
Efficacy evaluations will be performed every 14 weeks of treatment in both groups</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine, Interferon, Interleukin</intervention_name>
    <description>Capecitabine orally from day 1 to 14 at a dose of 1000 mg/m2 twice daily every 21 days.&#xD;
Interferon-alpha subcutaneously on days 1 + 3 + 5 weeks 1 + 2 +6 + 7,11+12 at a dose of 6 MIU/d.&#xD;
Interleukin-2 subcutaneously on days 1 to 4 in weeks 3 + 4 +8 + 9,13+14 at a dose of 4.5 MIU/day.&#xD;
Group B&#xD;
Patients randomized to group B will receive treatment according to the same treatment schedule and at the same dosages without capecitabine.&#xD;
Efficacy evaluations will be performed every 14 weeks of treatment in both groups</description>
    <arm_group_label>Capecitabine and Interferon</arm_group_label>
    <arm_group_label>Interferon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed renal cell carcinoma (primary tumour or biopsy/surgery of&#xD;
             metastases)&#xD;
&#xD;
          -  Radiologically confirmed metastatic disease&#xD;
&#xD;
          -  Surgically removed primary tumour so feasible (nephrectomy or nephron-sparing surgery&#xD;
             as indicated)&#xD;
&#xD;
          -  Karnofsky-Performance Status &gt;70%&#xD;
&#xD;
          -  Age 19-75 years&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Adequate bone marrow function (i.e. white blood cell count above 3000/μL, platelet&#xD;
             count above 75 000 /μL, hemoglobin above 9 mg/dl)&#xD;
&#xD;
          -  Adequate organ function (i.e. serum creatinine, bilirubin and AST below 1.25 x the&#xD;
             upper limit of the institutions' normal range)&#xD;
&#xD;
          -  Negative pregnancy test for female patients&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;19 or &gt;75 years&#xD;
&#xD;
          -  Karnofsky-Performance Status &lt; 70%&#xD;
&#xD;
          -  Untreated or uncontrolled brain metastases&#xD;
&#xD;
          -  Second neoplasia&#xD;
&#xD;
          -  Primary tumour surgically removable&#xD;
&#xD;
          -  Solitary, surgically removable metastases&#xD;
&#xD;
          -  Major concomitant diseases of the cardiovascular, respiratory or renal systems, as&#xD;
             well as active systemic infections&#xD;
&#xD;
          -  Severe renal disease or liver insufficiency or myeloid dysfunction (including patients&#xD;
             with a history of a disease that is likely to interfere with the metabolism or&#xD;
             excretion of the test medication)&#xD;
&#xD;
          -  Other less common diseases as peptic ulcer disease, inflammatory bowel disease,&#xD;
             autoimmune disease (severe known psoriasis, idiopathic thrombocytopenic purpura, lupus&#xD;
             erythematosus, autoimmune hemolytic anemia, scleroderma, rheumatoid arthritis etc.)&#xD;
&#xD;
          -  Drug addiction (including excessive alcohol consumption) within 1 year prior to study&#xD;
             start.&#xD;
&#xD;
          -  History of other conditions consistent with decompensated liver disease or other&#xD;
             evidence of bleeding form esophageal varices.&#xD;
&#xD;
          -  History of chronic hepatitis and immunsupressiva&#xD;
&#xD;
          -  Known HIV Infection&#xD;
&#xD;
          -  Evidence of allergy or hypersensitivity against recombinant Interferon alfa-2a or&#xD;
             other components of preparation.&#xD;
&#xD;
          -  History of severe psychiatric disease, especially depression. Severe psychiatric&#xD;
             disease is defined as treatment with an antidepressant medication or a major&#xD;
             tranquilizer at therapeutic doses for major depression or psychosis, respectively, for&#xD;
             at least 3 months at any previous time or any history of the following: a suicidal&#xD;
             attempt, hospitalization for psychiatric disease, or a period of disability due to a&#xD;
             psychiatric disease.&#xD;
&#xD;
          -  Seizure disorders and /or compromised central nervous system function.&#xD;
&#xD;
          -  History of evidence of severe retinopathy&#xD;
&#xD;
          -  Patient unwilling or unable to give informed consent&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuela Schmidinger, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univ. Klinik f. Innere Med. I, Abt. Onkologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univ. Klinik f. Innere Medizin, Abt. Onkologie</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.cecog.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>April 5, 2006</study_first_submitted>
  <study_first_submitted_qc>April 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2006</study_first_posted>
  <last_update_submitted>May 15, 2012</last_update_submitted>
  <last_update_submitted_qc>May 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

